Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Arvinas Inc.

< Previous 1 2 3 Next >
News headline image
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN NVS
News headline image
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces Chief Financial Officer Transition
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Appoints Jared Freedberg as General Counsel
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Arvinas Announces Oversubscribed $350 Million Private Placement
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
News headline image
Arvinas to Present at Stifel Targeted Oncology Day
From Arvinas Inc.
Via GlobeNewswire
Tickers ARVN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.